Teva Pharmaceutical Industries Gets Major Credit Rating Upgrade

TEL AVIV, Israel, Sept. 04, 2026 /CourierPR/ -- Teva Pharmaceutical Industries, the multinational pharmaceutical company, has seen a significant boost in its financial standing, as S&P Global Ratings upgraded the firm's long-term issuer credit rating to BBB-, marking its third credit rating upgrade in recent months. This upgrade comes alongside similar ratings improvements from Fitch and Moody’s, solidifying Teva's investment-grade status across all major rating agencies.

Eli Kalif, Teva's Chief Financial Officer, stated: "Teva’s recent trio of rating upgrades in just a few months reflects the strong execution of our Pivot to Growth strategy and the meaningful progress we have made in reducing debt and strengthening our financial profile. This significant milestone further enhances our financial flexibility to invest in growth and deliver long-term value."

According to S&P’s report, the upgrades are a testament to Teva’s sustainable growth prospects. The company’s success is attributed to its strong execution in branded products, the stabilization of its generics business, and the presence of significant late-stage assets in its pipeline. These factors have not only improved Teva’s credit profile but also bolstered its position in the competitive pharmaceutical market.

Teva Pharmaceutical Industries, founded over 120 years ago, has been at the forefront of advancing healthcare. The company is now transforming into a leading innovative biopharmaceutical firm, leveraging its robust generics business to drive innovation in fields such as neuroscience and immunology. Teva continues to develop complex generic medicines, biosimilars, and pharmacy brands, all aimed at addressing the evolving healthcare needs of patients globally.

Despite the positive news, Teva remains cautious, highlighting the risks associated with its financial and operational performance. In a forward-looking statement, the company emphasized that its future results, performance, or achievements could differ significantly from current expectations due to various factors, including the ability to maintain its financial ratings, the development and commercialization of new pharmaceutical products, and the competitive landscape in the pharmaceutical industry.

For investors and stakeholders, Teva’s ongoing financial discipline and strategic focus on growth provide a promising outlook for the future. The company remains committed to executing its Pivot to Growth strategy, which includes expanding its innovative and biosimilar medicines pipeline, profitably commercializing its portfolio, and sustaining its generic medicines business. These initiatives are expected to drive Teva's financial performance and create long-term value for shareholders.

Teva’s recent credit rating upgrades underscore the company’s resilience and continued commitment to financial prudence and strategic growth. As the firm moves forward, it aims to leverage its robust financial foundation to drive innovation and meet the evolving healthcare needs of the global population.